Search results
Results From The WOW.Com Content Network
List of largest biomedical companies by revenue. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$ 10 billion, ranked by their revenue in the respective financial year. It does not include biotechnology companies that ...
Between 8 December 2020 and 15 February 2021, 1,137,775 participants were vaccinated in the study, 490,000 of whom were given the Oxford–AstraZeneca vaccine. The first dose of the Oxford–AstraZeneca vaccine was associated with a vaccine effect of 94% for COVID-19-related hospitalisation at 28–34 days post-vaccination.
AstraZeneca plc ( / ˌæstrəˈzɛnəkə /) ( AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [ 2 ][ 3 ][ 4 ] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [ 5 ] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal ...
July 25, 2024 at 6:22 AM. Anglo-Swedish drugmaker AstraZeneca raised its full year sales and profit forecast on Thursday after beating analyst expectations for second-quarter revenue on strong ...
AstraZeneca has set a target to become an $80 billion company, in sales, by 2030. In 2023, the company booked $45.8 billion in revenue. CFO Aradhana Sarin said she is now focused on the execution ...
On Thursday, AstraZeneca Plc (NASDAQ:AZN) reported second-quarter sales of $12.94 billion, up 13% year over year (+17% at constant currency), beating the consensus of $12.75 billion. The company ...
A packet of AstraZeneca COVID-19 vaccine vials. A dispute broke out in January 2021 between the European Commission and the pharmaceutical company AstraZeneca AB about the provision of COVID-19 vaccines during the COVID-19 pandemic, [ 1] and, in February, spilled out into a dispute over Article 16 of the Northern Ireland Protocol. [ 2][ 3][ 4 ...
Show comments. AstraZeneca aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday, boosted by the expected launch of 20 new medicines and through growth in its cancer ...